Agios Pharmaceuticals | AGIO - Ordinary Share Capital


Agios Pharmaceuticals reported $59.34M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 540M 1000K Mar/2026
Arrowhead Research USD 140.57M 3.18M Mar/2026
Astellas Pharma JPY 1.79B 81K Mar/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bayer EUR 982.42M 0 Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Daiichi Sankyo JPY 1.82B 30.68M Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 253.7M 8.78M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026